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ABSTRACT
This study was designed to prospectively examine whether peptide nucleic acid 
clamping-assisted fluorescence melting curve analysis (PANAMutyper™) is feasible for 
the detection of activating and acquired resistant epidermal growth factor receptor 
(EGFR) mutation in plasma. Patients with non-small cell lung cancer harboring 
activating EGFR mutations who were scheduled to undergo EGFR-tyrosine kinase 
inhibitors (EGFR-TKIs) were enrolled between September 2011 and March 2015. A 
total of 102 patients with EGFR-mutated lung cancer were enrolled, 53 had available 
plasma samples at disease progression, and 28 underwent serial plasma sampling 
during EGFR-TKI treatment. EGFR-TKI-sensitizing and T790M mutations were 
detected in the plasma of 68.6% (70/102) at baseline and 30.2% (16/53) at disease 
progression, respectively. The concordance rates for matched tissue and plasma 
samples were 80.4% and 90.2% for E19del and L858R mutations at baseline and 
56.3% for T790M mutation at disease progression. The sustained presence of plasma 
EGFR mutations four weeks after EGFR-TKI predicted a poor objective response rate 
(30.0% vs. 87.5%, P = 0.025), as well as worse progression-free survival (hazard 
ratio [HR], 4.381) and overall survival (HR, 5.475). Longitudinal analysis could detect 
T790M mutations earlier than disease progression based on imaging study (median 
time from appearance of T790M in plasma samples to progression at imaging scan, 
103 days). In conclusion, PANAMutyper™ is reliable for detecting activating and 
acquired resistant EGFR mutation in plasma, and predicts responses to EGFR-TKI via 
longitudinal monitoring of EGFR mutation during treatment.
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INTRODUCTION
Activating epidermal growth factor receptor 
(EGFR) mutations are predictive biomarkers for response 
to EGFR-tyrosine kinase inhibitors (EGFR-TKIs; e.g., 
erlotinib, gefitinib or afatinib) and EGFR-TKIs are 
the standard first-line therapy for non-small cell lung 
cancer (NSCLC) with activating EGFR mutations [1–3]. 
Randomized phase III studies have consistently 
demonstrated that first-line EGFR-TKI therapy improves 
progression-free survival (PFS) compared with standard 
cytotoxic chemotherapy in EGFR mutated lung cancer 
patients [2–4]. However, most patients treated with 
EGFR-TKI ultimately develop disease progression due 
to acquired resistance via multiple mechanisms [5–7]. 
Of these mechanisms, EGFR T790M mutation accounts 
for more than 50% of the acquired resistance [8]. Third-
generation EGFR-TKIs have shown promising activity 
against EGFR T790M mutation-positive NSCLC and 
recently osimertinib was approved by the US Food and 
Drug Administration [9]. Therefore, in the era of third 
generation EGFR-TKI, the detection of EGFR T790M 
mutation in repeated biopsies at the time of EGFR-TKI 
failure is indispensable to improving survival outcomes in 
EGFR mutated patients.
Analysis of EGFR mutations in tumor tissue is not 
always possible due to the invasive nature of biopsies, 
inaccessibility of tumor location, or low quantity and 
quality of the tissue samples [10, 11]. Moreover, single-
site biopsy cannot provide a representative profile of the 
overall resistance mechanisms for patients with multiple 
metastatic sites with heterogeneous characteristics [12]. In 
reality, a monitoring of mutation dynamics during EGFR-
TKI through repetitive biopsies is not suitable. Detection 
of circulating free tumor DNA (ctDNA) in plasma has been 
considered as a feasible method for diagnosis, prediction 
of treatment efficacy, and monitoring of recurrence or 
disease burden in various solid tumors in recent years 
[13–15]. In meta-analyses, ctDNA has proven to be a 
highly specific and effective biomarker for the detection of 
activating EGFR mutation in NSCLC [16, 17]. The T790M 
mutation was also successfully detected by liquid biopsy 
through analysis of blood samples [18, 19]. Compared to 
tumor tissue biopsy, liquid biopsy for detecting ctDNA is 
safer because of its non-invasive nature and more feasible 
for monitoring tumor dynamics as it is representative of 
multiple tumor sites [20].
Peptide nucleic acids (PNA) are synthetic polymers 
that bind tightly to a complementary sequence in DNA 
[7, 21]. Despite its lack of ability to detect new mutations, 
PNA-mediated polymerase chain reaction (PCR) 
clamping assay has advantages of sensitivity, simplicity, 
and speed for detecting previously known mutations and 
thus, real-time PCR with PNA has been widely used to 
detect EGFR mutation. Recently, the Korean Food and 
Drug Administration approved the PNA Clamp™ EGFR 
Mutation Detection kit (PANAGENE Inc., Daejeon, 
Korea) as a standard screening method for EGFR mutation 
in lung cancer patients [21, 22]. To increase the sensitivity 
of the PNA clamp method in order to detect even in 
plasma ctDNA, PNA clamping-assisted fluorescence 
melting curve analysis (PANAMutyper™ EGFR kit) was 
newly developed using a fluorescence melting curve in 
addition to PNA clamping.
In this study, we prospectively evaluated whether 
PNA clamping-assisted fluorescence melting curve 
analysis (PANAMutyper™) can accurately detect activating 
and acquired resistance EGFR mutations in plasma ctDNA 
derived from NSCLC patients. Additionally, we aimed to 
explore dynamic changes in EGFR mutation profiles and 
the appearance of acquired resistance during EGFR-TKI 
in EGFR mutated lung cancer patients.
RESULTS
Patient characteristics and treatment outcomes 
for EGFR-TKI
A total of 102 patients with NSCLC harboring 
activating EGFR mutations were enrolled in this 
prospective trial of first-generation EGFR-TKI between 
September 2011 and March 2015 at Yonsei Cancer Center 
in Korea (Figure 1). Baseline examination of EGFR 
mutations was performed in 102 patients using matched 
tumor tissues and plasma samples (Table 1). The majority 
were female (62/102, 60.8%), never smokers (71/102, 
69.6%) with extra-thoracic metastatic disease (M1b) 
(71/102, 69.6%) who received gefitinib (81/102, 79.4%) 
as the first-line treatment (72/102, 70.6%). The most 
common mutation identified was E19del (57/102, 55.9%) 
and T790M was not detected in any patients at baseline. 
Objective responses were observed in 64 patients (62.8%), 
including a complete response in one patient (1/102, 
1.0%) and a partial response in over half of the patients 
(63/102, 61.8%). The median PFS was 13.6 months (95% 
confidence interval [CI], 11.6–15.6 months) and the 
median overall survival (OS) was 28.6 months (95% CI, 
12.2–45.0 months). During a median follow-up period 
of 36.4 months (95% CI, 31.8–41.1 months), disease 
progression and death events occurred in 67 (65.7%) and 
40 (39.2%) patients, respectively. Dynamic changes in 
EGFR mutations were analyzed in 28 patients using serial 
sampling (Supplementary Table 1). At the time of disease 
progression, 53 blood samples were available, including 
16 paired tissue biopsies and blood samples. All causes of 
death were related to disease progression.
Performance of the platform
EGFR E19del or L858R mutations were detected 
in baseline plasma samples prior to treatment in 68.6% 
(70/102) of the patients (Table 2). Sensitivity of M1b 
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disease was higher than that of M0/M1a disease (83.1% 
vs. 35.5%, P < 0.001). Likewise, median copy numbers 
of activating EGFR mutation were higher in M1b than in 
M0/M1a disease (1422.7 copies/mL vs. 431.5 copies/mL, 
P < 0.001). Concordance rate, sensitivity, and negative 
predictive value (NPV) between plasma ctDNA and 
matched tissue were 80.4% (80/102), 61.8% (35/57), and 
67.2% (45/67) for E19del and 90.2% (92/102), 77.8% 
(35/45), and 85.1% (57/67) for L858R. E19del mutations 
were not detected in plasma from patients with L858R 
mutations and vice versa, yielding a specificity and 
positive predictive value (PPV) of 100% for both subtypes 
of EGFR mutation.
Monitoring of acquired resistance during serial 
sampling and at disease progression
A decrease in copy numbers of activating plasma 
EGFR mutation (E19del or L858R) was seen in 94.4% 
of the patients (17/18) four weeks after administration of 
EGFR-TKI, except one patient who progressed within 81 
days and revealed detectable plasma T790M at 28 days 
after treatment (Figure 2). Genomic profiling of tumor 
tissue from this non-responder by next-generation 
sequencing revealed mutations in TP53, as well as 
STK11, which is known to be associated with de novo 
resistance to EGFR-TKI [23]. Negative conversion of 
detectable plasma EGFR mutation was seen in 44.4% 
of the patients (8/18), and the median rates of decrease 
in copy numbers was 67.9% (range, 11.3%–100.0%). 
Re-emergence or increasing copy numbers of activating 
EGFR mutation in plasma was also observed before 
objective disease progression based on imaging scans 
according to Response Evaluation Criteria in Solid 
Tumors (RECIST) 1.1 guidelines. Emergence of acquired 
resistance (T790M) was always associated with disease 
progression which was later evaluated based on imaging 
scan. Median time from appearance of T790M in plasma 
samples to progression at imaging scan was 103 days 
(range, 0–169 days).
Among the 67 patients who experienced disease 
progression after EGFR-TKI treatment, 53 patients had 
blood plasma samples available at the time of disease 
progression (Table 3). The prevalence of T790M mutation 
in plasma was 30.2% (16/53). Comparison between 
matched tumor tissues by repeated biopsy and plasma at 
disease progression was performed in 16 patients (Table 
4). The prevalence of the T790M mutation was 37.5% 
(6/16) for tissue samples and 31.3% (5/16) for plasma 
samples. The concordance rate of T790M mutations 
between tissue and plasma samples was 56.3% (9/16). 
Seven cases with discrepancies in T790M mutations 
included three patients who were positive for the T790M 
mutation in plasma but negative in tissue samples and 
four patients who showed the reverse. In examination of 
both tissue and plasma samples, resistance mechanisms to 
EGFR-TKIs were driven by secondary T790M mutations 
(9 patients), c-MET amplification by fluorescent in 
situ hybridization (1 patient), small cell transformation 
(1 patient), epithelial-to-mesenchymal transition by 
histologic analysis (1 patient), and unknown causes (4 
patients).
Prognostic and predictive value of ctDNA from 
blood plasma samples. Median PFS was 11.9 months 
for patients with detectable plasma EGFR mutations 
before treatment versus 21.4 months for those without 
detectable mutations (hazard ratio [HR], 2.964; 95% 
CI, 1.624–5.409; P < 0.001; Figure 3A) and median 
OS was 18.8 versus 37.6 months, respectively (HR, 
2.790; 95% CI, 1.274–6.110; P = 0.007; Figure 
3B). Objective response rates were not significantly 
different between the two groups. In analysis adjusted 
for other demographic and clinicopathologic variables, 
detectable plasma EGFR mutation before EGFR-TKI 
Figure 1: Patients with available tissue or plasma samples before administration of EGFR-TKI, during course of 
treatment, and after progression.
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was independently associated with worse PFS (HR, 
2.694; 95% CI, 1.416–5.125) and OS (HR, 2.436; 
95% CI, 1.040–5.704), respectively (Table 5). Of the 
28 patients who underwent serial plasma sampling, 18 
patients (64.3%) had detectable EGFR mutations before 
EGFR-TKI treatment. Moreover, the presence of EGFR 
mutation after treatment might predict poor prognosis of 
these patients. Median PFS was 2.7 months for patients 
with detectable plasma EGFR mutation, even after four 
weeks of treatment versus 14.1 months for patients 
without detectable mutations (HR, 4.381; 95% CI, 1.340–
14.316; P = 0.016; Figure 3C), whereas median OS was 
18.6 months versus not reached, respectively (HR, 5.475; 
95% CI, 1.425–21.035; P = 0.020; Figure 3D). Objective 
response rates after four weeks of treatment were 30.0% 
for patients with detectable plasma EGFR mutation 
and 87.5% for patients without detectable mutation 
P = 0.025).
Table 1: Baseline characteristics and treatment outcomes of patients (N = 102)
Variables N %
Age (years)
Median 61
Range 33–84
Gender
Male 40 39.2
Female 62 60.8
Smoking history
Never-smoker 71 69.6
Ever smoker 31 30.4
Stage
M0/M1a 31 30.4
M1b 71 69.6
Type of EGFR mutation
E19del 57 55.9
L858R 45 44.1
Line of treatment
1st 72 70.6
2nd 30 29.4
TKI
Erlotinib 21 20.6
Gefitinib 81 79.4
Best response
Complete response 1 1.0
Partial response 63 61.8
Stable disease 33 32.4
Progressive disease 2 2.0
Not assessable 3 2.9
Abbreviations: E19del, exon 19 deletion; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
Table 2: Comparison between plasma and tissue samples at baseline
Tissue EGFR mutation
E19del L858R Total patients
ctDNA EGFR mutation
E19del 35 0 35
L858R 0 35 35
Wild 22 10 32
Total patients 57 45 102
Abbreviations: ctDNA, circulating free tumor DNA; E19del, exon 19 deletion; EGFR, epidermal growth factor receptor.
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In the case of a 56-year-old female who developed 
acquired resistance after 9 months’ treatment with 
erlotinib (Figure 4), a plasma sample obtained at disease 
progression revealed both EGFR E19del and T790M 
mutations within 48 hours after sampling. A confirmatory 
lung biopsy was also performed, which revealed only 
an EGFR E19del mutation 23 days after the procedure. 
Treatment with a third-generation TKI, HM61713, was 
subsequently initiated and the patient exhibited a partial 
response to therapy, which continues to be maintained. 
The benefits of liquid biopsy including delicate reflection 
of tumor heterogeneity as well as fast turn-around time can 
be seen in this case.
DISCUSSION
This is the first prospective study demonstrating 
the feasibility of PNA clamping-assisted fluorescence 
melting curve analysis (PANAMutyper™) of plasma 
ctDNA derived from NSCLC patients with activating 
and acquired resistant EGFR mutations. The overall 
sensitivity and specificity of this platform were 68.6% 
and 100% at baseline, respectively. Longitudinal plasma 
analysis was found to detect acquired resistance earlier 
than that of tumor tissue biopsies, and demonstrated 
that the prevalence of activating and resistant mutations 
increased over time before progression. Presence of 
EGFR mutations in plasma prior to EGFR-TKI treatment 
was associated with impaired survival outcomes. In most 
patients, DNA copy numbers of activating EGFR mutation 
decreased in plasma within four weeks after EGFR-TKI. 
Interestingly, the presence of detectable plasma EGFR 
mutation four weeks after EGFR-TKI was associated with 
lower objective response rates and shorter PFS and OS 
than the absence of mutation.
Recent studies suggest that EGFR mutation analysis 
with ctDNA through liquid biopsy can be an alternative 
detection method for patients who cannot receive invasive 
procedures for tissue analysis [19, 24]. High specificity 
was observed consistently in several different platforms, 
although false-negative results are still an important issue 
regarding the diagnostic value of blood-based analysis 
in clinical practice. Kim et al. reported that the overall 
sensitivity of EGFR mutations in ctDNA was 17.1% 
Figure 2: Representatives for longitudinal monitoring of activating and resistant EGFR mutations in ctDNA. Each 
graph (A–E) represents each patient.
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Table 3: Subtypes of ctDNA EGFR mutation at disease progression (N = 53)
ctDNA EGFR mutation N %
E19del 8 15.1
E19del, T790M 9 17.0
L858R 9 17.0
L858R, T790M 6 11.3
T790M 1 1.9
Wild 20 37.7
Abbreviations: ctDNA, circulating free tumor DNA; E19del, exon 19 deletion; EGFR, epidermal growth factor receptor.
Table 4: Comparison between plasma and tissue samples at disease progression
E19del
Tissue EGFR mutation
E19del, T790M L858R L858R, T790M T790M Total patients
ctDNA EGFR 
mutation
E19del 1 1 0 0 0 2
E19del,T790M 2 1 0 0 0 3
L858R 0 0 1 2 0 3
L858R,T790M 0 0 1 1 0 2
Wild 5 0 0 0 1 6
Total patients 8 2 2 3 1 16
Abbreviations: ctDNA, circulating free tumor DNA; E19del, exon 19 deletion; EGFR, epidermal growth factor receptor.
Figure 3: Kaplan–Meier survival estimates for patients according to plasma EGFR mutation. PFS (A) and OS (B) by 
ctDNA status at baseline. PFS (C) and OS (D) by ctDNA status four weeks after treatment.
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with PNA-mediated PCR clamping [25]. Similarly, the 
sensitivity of PNA PCR clamping was low at 22.2% (4/18) 
in our independent analysis (Supplementary Table 2). On 
the other hand, by incorporating melting curve analysis 
to PNA-mediated PCR clamping method, the sensitivity 
of this platform (PANAMutyper™) increased up to nearly 
70%, similar to previous studies conducted by Han 
et al [26]. This result was comparable to previous studies 
using the non-digital amplification refractory mutation 
system (ARMS) assay [27], allele-specific PCR assay 
[28], next generation sequencing (NGS) [29], and droplet 
digital PCR (ddPCR) assay [30]. In comparison with other 
methods, PANAMutyper™ can be performed simply with 
real-time PCR and finished in a brief time [7]. Furthermore, 
it can simultaneously detect multiple mutations while 
maintaining high sensitivity and specificity [31].
Although EGFR-TKI prolonged survival outcome 
of patients with activating EGFR mutation, this benefit 
was not distributed equally among patients [1, 3]. Hence, 
plasma-based EGFR mutation analysis has been used to 
monitor responses to EGFR-TKI in previous studies. Mok 
et al. reported an association of negative conversion of 
EGFR mutation of ctDNA 12 weeks after treatment along 
with prolonged PFS and OS [28]. Lee et al. also showed 
that detectable EGFR mutation in plasma during the course 
of treatment was associated with impaired outcomes [30]. 
In line with these previous studies, the predictive value 
of plasma EGFR mutation after treatment was proven in 
the present study. In addition to confirming the correlation 
of PFS and OS with dynamic changes in EGFR mutation 
status, we also demonstrated that radiologic response 
according to RECIST criteria was correlated with post-
treatment plasma EGFR mutation status. We evaluated the 
predictive value of an early response reflected by ctDNA 
at four weeks after treatment, which is earlier than other 
previous studies [28, 32]. Considering that outcomes for 
patients who continued to have detectable plasma EGFR 
mutation four weeks after treatment were relatively poor, 
assessment of plasma EGFR mutation status four weeks 
after treatment can help in timely discrimination of 
patients who may benefit from continuing EGFR-TKI.
T790M is the most common mutation associated 
with acquired resistance to first-generation EGFR-
TKIs [8]. The development of third-generation TKIs has 
substantially benefitted patients with acquired resistance to 
erlotinib or gefitinib [9, 19]. Because of the limitation of 
Table 5: Multivariate analysis of prognostic factors with progression-free survival and overall 
survival
Progression-free survival Overall survival
HR (95% CI) P value HR (95% CI) P value
Gender 0.239 0.237
Female Ref Ref
Male 0.580 (0.234–1.435) 0.444 (0.116–1.706)
Smoking history 0.123 0.271
Never-smoker Ref Ref
Ever smoker 2.139 (0.813–5.629) 2.230 (0.534–9.312)
Stage 0.248 0.410
M0/M1a Ref Ref
M1b 1.502 (0.753–2.994) 1.466 (0.590–3.643)
Type of EGFR mutation 0.983 0.100
E19del Ref Ref
L858R 0.995 (0.598–1.654) 1.981 (0.877–4.476)
Line of treatment 0.302 0.099
1st Ref Ref
2nd 1.321 (0.778–2.243) 1.798 (0.896–3.606)
TKI 0.803 0.736
Gefitinib Ref Ref
Erlotinib 1.087 (0.566–2.086) 1.149 (0.512–2.581)
Presence of pretreatment ctDNA 0.003 0.040
No Ref Ref
Yes 2.694 (1.416–5.125) 2.436 (1.040–5.704)
Abbreviations: CI, confidence interval; ctDNA, circulating free tumor DNA; E19del, exon 19 deletion; HR, hazard ratio; Ref, 
referent; TKI, tyrosine kinase inhibitor.
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repeated biopsies, several studies have evaluated acquired 
resistance using non-invasive blood-based analyses 
[15, 24]. In the present study, the T790M mutation was 
found in 16 of 53 patients (30.2%), and was detectable as 
early as six months before objective disease progression. 
The relative proportion of T790M mutations increased 
after the first appearance of such acquired resistance, 
and all patients with detectable T790M in serial plasma 
samples eventually experienced disease progression.
When we compared EGFR mutation results of 
tumor tissues and plasma samples at disease progression, 
18.8% of patients (3/16) had detectable T790M in plasma 
that was not detected via tissue biopsy. This discrepancy 
could result from the heterogeneous nature of metastatic 
tumor deposits [33, 34]. The concordance rate between 
plasma and tissue for E19del or L858R before EGFR-TKI 
was higher than that for T790M at disease progression 
(80.4% and 90.2%, respectively, vs. 56.3%). Therefore, 
confounding results of repeat biopsy can be supplemented 
by non-invasive blood-based methods. Studies focusing 
on the clinical relevance of early detection of resistant 
mutations in ctDNA or discrepancy of T790M between 
tumor tissue and plasma samples are underway using 
ARMS and ddPCR methods (NCT02418234).
Unfortunately, the predictive role of T790M in 
plasma could not be fully assessed in this study, because 
of the small number of patients who underwent plasma 
sampling at disease progression or received subsequent 
treatment with the third-generation TKI. In addition, 
repeated tumor biopsy after disease progression was 
performed in only a small number of patients (16/67, 
23.9%), mainly because of clinical deterioration.
In conclusion, PNA clamping-assisted fluorescence 
melting curve analysis (PANAMutyper™) in plasma 
samples is a feasible and effective method for diagnosis 
of activating mutation, prediction of treatment response, 
and monitoring of acquired resistance during EGFR-TKI 
treatment. Larger studies on the clinical relevance of 
T790M genotyping based on this platform are warranted to 
confirm our results. Ultimately, prospective clinical trials 
exploring the correlation with response to third-generation 
EGFR-TKI therapy could help validate the usefulness of 
this platform for T790M genotyping in clinical practice.
MATERIALS AND METHODS
Study design
This study was an exploratory trial to evaluate 
the performance of a newly developed platform 
(PANAMutyper™) for detecting activating and acquired 
resistant EGFR mutation in plasma from NSCLC patients 
harboring EGFR mutation during EGFR-TKI. Patients 
with NSCLC harboring activating EGFR mutations were 
Figure 4: A patient with metastatic NSCLC with acquired resistance to erlotinib who showed a partial response to 
third-generation TKI.
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enrolled in a prospective trial of first-generation EGFR-TKI 
(gefitinib or erlotinib) at Yonsei Cancer Center in Korea. 
Activating EGFR mutations were defined as mutations 
known to be associated with EGFR-TKI sensitivity, including 
E19del and L858R. Patients with available archival tissue 
and those with measurable lesions at baseline were enrolled. 
Baseline tissue and blood plasma samples were collected 
before EGFR-TKI administration. Serial plasma sampling 
and tissue or plasma sampling at the time of progression 
were optional in our trial. This study was approved by the 
Institutional Review Board and the ethics committee of 
Yonsei Cancer Center. All patients provided written informed 
consent for study participation and genetic analysis.
Study objectives
The primary objective was to assess the diagnostic 
utility of plasma sampling using matched tissue and 
plasma samples. Sensitivity, specificity, PPV, NPV, and 
concordance rate were analyzed in comparison to specific 
tissue EGFR mutation status. Secondary objectives 
included assessment of the prognostic and predictive value 
of plasma EGFR mutations at baseline and serial sampling, 
monitoring acquired resistance, and comparison between 
tissue and plasma samples upon disease progression.
Treatment and evaluation of response
Patients received erlotinib at 150 mg/d or gefitinib 
at 250 mg/d. Evaluation of response by computed 
tomography scans was performed four weeks after the 
baseline study, and then every eight weeks thereafter 
according to the RECIST 1.1 guidelines. Serial sampling 
was performed at the time of response evaluation. 
Treatment was continued until disease progression, 
intolerable toxicity, or withdrawal of consent.
Data collection
Medical records and radiologic images of all 
patients were collected to evaluate demographic and 
clinicopathologic parameters, tumor response, PFS, and 
OS. Never smokers were defined as those with a lifetime 
smoking dose of less than 100 cigarettes. PFS was 
measured from the first day of treatment with EGFR-TKI 
to tumor progression or death. OS was measured from the 
first date of treatment with EGFR-TKI until the date of 
death. Patients were censored at the last visiting if alive and 
progression-free. Sensitivity, specificity, PPV, NPV, and 
concordance rate were calculated for E19del, L858R, and 
T790M mutations as described in Supplementary Table 3.
DNA extraction
Tumor DNA was extracted using the Maxwell R 16 
FFPE purification kit (Promega, Mannheim, Germany) 
and ctDNA was extracted from 1 mL of plasma using 
the QIAamp MinElute Virus Spin kit (QIAGEN, Hilden, 
Germany) according to the manufacturers’ protocols.
EGFR mutation analysis for tissue 
We used the PNAClamp™ EGFR Mutation Detection 
kit (PANAGENE Inc., Daejeon, Korea) to detect EGFR 
mutations by real-time PCR. All reactions were performed 
in 20 µl volumes containing template DNA, primer and 
PNA probe sets, and fluorescence PCR master mix. All 
reagents were included in the kit. Real-time PCR reactions 
of PNA-mediated clamping PCR were performed using 
a CFX 96 system (Bio-Rad, Hercules, CA, USA). PCR 
cycling conditions were a 5 min hold at 94°C, followed 
by 40 cycles of 94°C for 30 sec, 70°C for 20 sec, 63°C for 
30 sec, and 72°C for 30 sec. The lowest mutation allele 
frequency for the E19del, L858R, and T790M mutations 
measured by the PNAClamp™ EGFR was set as 1.0%, 
corresponding to one mutated copy in 100 copies of wild 
type DNA (Supplementary Figure 1).
EGFR mutation analysis for plasma 
The PANAMutyper™ EGFR kit was used for 
mutation detection. The PANAMutyper™ EGFR kit 
is a newly developed mutation detection kit designed 
to detect 47 different EGFR variants in exons 18–21 
with high sensitivity using PNA clamping-assisted 
fluorescence melting curve analysis for mutation detection 
and genotyping. All reactions were performed in a 
total volume of 25 µl that contained 10–25 ng of DNA 
templates, primer and PNA probe sets, and PCR master 
mix. All reagents used were included with the kit. PCR 
was performed under the following conditions: 50°C 
for 2 min and 95°C for 15 min as two holding periods; 
15 cycles of 95°C for 30 sec, 70°C for 20 sec, 63°C for 
60 sec; 35 cycles of 95°C for 10 sec, 53°C for 20 sec, 
73°C for 20 sec; and a melting curve step (from 35°C 
to 75°C with gradual increment for 0.5°C for 3 sec). 
Fluorescence was measured on all four channels (FAM, 
ROX, Cy5, and HEX). Melting peaks were derived from 
the melting curve data. Mutations were detected by the 
melting temperature of each tube for each fluorescent dye 
as shown in Supplementary Table 4. 
The total amount of plasma volume required 
for assay was 1 mL and all samples were successfully 
genotyped. The median amounts of amplifiable DNA 
extracted from plasma for E19del, L858R, and T790M 
were 711.6 (range, 0–8707.3), 206.1 (range, 0–1721.7), 
and 68.5 (range, 0–1262.9) copies/mL, respectively. The 
lowest mutation allele frequency for the E19del, L858R, 
and T790M mutations measured by the PANAMutyper™ 
was set as 0.01%, corresponding to one mutated copy 
in 10,000 copies of wild type DNA (Supplementary 
Figure 2). This cut-off value yielded 100% specificity 
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when plasma derived from 10 healthy volunteers 
(ZenBio Inc., Durham, NC, USA) and normal genomic 
DNA (Horizon Dx Inc., Cambridge, UK) was tested 
(Supplementary Figure 3). All results were available 
within three hours with this ready-to-use kit.
Statistical analysis
Fisher’s exact test and Wilcoxon rank-sum test 
were used for categorical and continuous variables. 
Survival distribution was estimated by the Kaplan–Meier 
method, and the Cox proportional hazards model was 
used to analyze the effect of specified risk factors on 
survival. Results were considered statistically significant 
at a P value < 0.05. All analyses were performed using 
statistical software package SPSS for Windows software, 
version 22.0 (SPSS Inc., Chicago, IL, USA).
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